Chemotherapy Biotherapy Certification ONS Practice Testq

Disable ads (and more) with a membership for a one time $2.99 payment

Prepare for the ONS Chemotherapy Biotherapy Certification Exam. Leverage flashcards and multiple choice questions, complete with hints and explanations. Equip yourself for exam success!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.


What is the key function of a monoclonal antibody therapy in cancer treatment?

  1. Boosting immune system overall

  2. Delivering a lab-made toxic substance to cancer cells

  3. Enhancing red blood cell production

  4. Increasing the production of white blood cells

The correct answer is: Delivering a lab-made toxic substance to cancer cells

Monoclonal antibody therapy plays a significant role in cancer treatment by specifically targeting cancer cells. The correct answer highlights that these therapies can be designed to deliver a lab-made toxic substance directly to the cancer cells. This targeted approach allows for a more direct assault on the cancerous cells while minimizing damage to surrounding healthy tissues. Monoclonal antibodies can recognize and bind to specific antigens present on the surface of cancer cells. Once bound, they can serve multiple functions, one of which includes being conjugated with a cytotoxic agent. This combination transforms the monoclonal antibody into a delivery vehicle that can selectively transport the toxic substance to the cancer cells, enhancing the efficacy of the treatment and reducing systemic side effects. This targeted mechanism contrasts with the other options, which do not accurately reflect the primary function of monoclonal antibodies in oncology. For instance, while boosting the overall immune system may play a role in cancer therapy, this is a broader approach often associated with immunotherapy rather than the specific action of monoclonal antibodies. Similarly, enhancing the production of red or white blood cells relates to different therapeutic strategies and is not the core function of monoclonal antibodies aimed specifically at malignancies.